NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx Inc (NASDAQ:CCXI) released its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.06. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analysts' expectations of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. View ChemoCentryx's Earnings History.

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

7 Wall Street analysts have issued 12-month price objectives for ChemoCentryx's shares. Their forecasts range from $22.00 to $56.00. On average, they expect ChemoCentryx's share price to reach $41.33 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for ChemoCentryx.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

News stories about CCXI stock have been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ChemoCentryx earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for ChemoCentryx.

ChemoCentryx saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,030,000 shares, a drop of 29.5% from the December 15th total of 2,880,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 5.0% of the company's stock are sold short. View ChemoCentryx's Current Options Chain.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Arrowhead Pharmaceuticals (ARWR), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Opko Health (OPK), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD) and Amarin (AMRN).

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $43.66.

ChemoCentryx has a market capitalization of $2.53 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.

The official website for ChemoCentryx is http://www.chemocentryx.com/.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]